The companies will use Personalis' ACE ImmunoID next-generation sequencing platform to analyze tumor samples from clinical trials of Argos' drug.
In Genome Biology this week: variants linked to disorders of sex development, new candidate genes for ciliopathies, and more.
A renal cell carcinoma study revealed increased metabolic gene expression in PD-L1-positive tumors from individuals who did not respond to nivolumab.
In Genome Biology this week: methylation changes in aging, single-cell RNA sequencing of renal cell carcinoma tumor, and more.
A Baylor College of Medicine-led team uncovered nine genomic subtypes of kidney cancer that may help direct patients' treatments.
Members of TCGA characterized papillary renal cell carcinomas, uncovering two main tumor groups and several more prognostically informative subtypes.
Roche is investigating the drug candidate for non small cell lung cancer, triple-negative breast cancer, and renal cell carcinoma.
Rosetta Genomics has published a study describing the development and initial validation of its miRview Kidney test, a 24-microRNA array-based assay that classifies a patient's primary kidney tumor into one of four main subtypes.
CHICAGO — Cancer Genetics will later this year expand its menu of array-based tests to include assays for informing treatment of patients with diffuse large B-cell lymphoma and renal cell carcinoma.
By Adam Bonislawski
Biodesix said this week that it is collaborating with pharma firm Kadmon on a 620-patient Phase III clinical trial of that company's reversible tyrosine kinase inhibitor KD019.
In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.
Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.
HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.
Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.